Literature DB >> 18760121

Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy.

Reinaldo B Bestetti1, Tatiana A D Theodoropoulos, Augusto Cardinalli-Neto, Patrícia M Cury.   

Abstract

The treatment of chronic heart failure secondary to Chagas disease has been based on extrapolation of data achieved in the treatment of non-Chagas disease heart failure. Because beta-blockers decrease the incidence of sudden cardiac death in non-Chagas disease heart failure and sudden cardiac death occurs preferentially in patients with mild Chagas disease heart failure, beta-blockers may be administered first to class I/II patients with Chagas disease heart failure. In advanced Chagas disease heart failure, angiotensin-converting enzyme inhibitor and diuretics may be given at first to compensate for congestive symptoms. After clinical status improvement, beta-blockers should be given at targeted doses, if necessary reducing angiotensin-converting enzyme inhibitor doses. Primary and secondary prevention of sudden cardiac death may be accomplished with implantable cardioverter defibrillators because of the high recurrence of life-threatening arrhythmias despite amiodarone administration. In refractory heart failure, heart transplantation is the treatment of choice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18760121     DOI: 10.1016/j.ahj.2008.04.023

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Aortic Counterpulsation Therapy in Patients with Advanced Heart Failure: Analysis of the TBRIDGE Registry.

Authors:  Cristiano Guedes Bezerra; Eduardo Leal Adam; Mariana Lins Baptista; Giuliano Serafino Ciambelli; Liliane Kopel; Claudia Bernoche; Leonardo Nicolau Geisler Daud Lopes; Milena Frota Macatrão-Costa; Breno de Alencar Araripe Falcão; Silvia Gelas Lage
Journal:  Arq Bras Cardiol       Date:  2015-12-22       Impact factor: 2.000

2.  Chagas Heart Failure in Patients from Latin America.

Authors:  Reinaldo B Bestetti
Journal:  Card Fail Rev       Date:  2016-11

3.  Prognostic Significance of Chronic Kidney Disease (CKD-EPI Equation) and Anemia in Patients with Chronic Heart Failure Secondary to Chagas Cardiomyopathy.

Authors:  Marcelo Arruda Nakazone; Maurício Nassau Machado; Ana Paula Otaviano; Ana Maria Silveira Rodrigues; Augusto Cardinalli-Neto; Reinaldo Bulgarelli Bestetti
Journal:  Cardiol Res Pract       Date:  2020-07-06       Impact factor: 1.866

4.  Cardiac resynchronization therapy for patients with chronic systolic heart failure secondary to Chagas cardiomyopathy in the 21st century.

Authors:  Reinaldo B Bestetti
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jan-Mar

Review 5.  Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death.

Authors:  Antonia Pino-Marín; Germán José Medina-Rincón; Sebastian Gallo-Bernal; Alejandro Duran-Crane; Álvaro Ignacio Arango Duque; María Juliana Rodríguez; Ramón Medina-Mur; Frida T Manrique; Julian F Forero; Hector M Medina
Journal:  Pathogens       Date:  2021-04-22

6.  The use of the CALL Risk Score for predicting mortality in Brazilian heart failure patients.

Authors:  Marcelo Arruda Nakazone; Ana Paula Otaviano; Maurício Nassau Machado; Reinaldo Bulgarelli Bestetti
Journal:  ESC Heart Fail       Date:  2020-07-01

Review 7.  Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine.

Authors:  Antonio Carlos Pereira-Barretto
Journal:  Am J Cardiovasc Drugs       Date:  2016-04       Impact factor: 3.571

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.